UNSPSC 51162639: Nepinalone

This classification denotes an antitussive agent with the molecular formula C18H25NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) L9806LPR7G, chemically known as (- )-3,4-dihydro-1-methyl-1-(2-piperidinoethyl)-2(1h)-naphthalenone. but more generally known as nepinalone, which bears US NIH Compound Identifier 3047788. European Medicines Agency schedules Nepinalone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09200MIG.

UNSPSC 51162639 Nepinalone is a Commodity code under which state and local governments procure naloxone (opioid-overdose reversal medication) and related drug-deactivation systems, along with broader generic pharmaceuticals and over-the-counter products distributed through state and multi-state cooperative purchasing agreements. The work spans emergency-response supply chains, public-health initiatives, and pharmacy operations at the county, state, and multi-state cooperative level. Issuing bodies include county health departments (Seminole County, Florida), state procurement offices (Minnesota Department of Administration), and multi-state cooperative purchasing alliances such as MMCAP, which coordinate buys across participating jurisdictions to achieve volume pricing and supply-chain standardization.

Recent activity spans Florida and the Upper Midwest. Seminole County issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug-deactivation systems annually with quarterly deliveries to its community health building, with bids due July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities including Oregon, with responses due March 26, 2026 and contract effectiveness targeted for July 1, 2026. MMCAP's RFP requires vendors to supply through three authorized wholesalers, certify cGMP and Drug Supply Chain Security Act compliance, maintain commercial general liability insurance of $5 million per occurrence, and accept a 3 percent administrative fee on all contract purchases.